Hook & thesis
Two events — a commercial regulatory milestone for Pixclara and regulatory alignment to advance TLX591-Tx into Part 2 of the ProstACT Global Phase 3 study - create a near-term asymmetric trade in Telix (TLX). The company now combines growing recurring diagnostic revenue with a progressing therapeutic pipeline. That mix moves Telix from 'pure R&D story' toward a hybrid commercial/pipeline company, which justifies taking a long position here.
My trade: enter at $11.90, stop at $10.00, target at $17.00
What Telix does and why it matters Telix Pharmaceuticals operates across three segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The company is building a two-pronged franchise. On the one hand, Precision Medicine is already producing meaningful commercial revenue through diagnostic imaging products and services. On the other, Therapeutics is advancing targeted radionuclide therapies (notably TLX591-Tx for metastatic prostate cancer) into later-stage clinical development. Why should the market care? Because this is one of the few radiopharmaceutical companies with both growing commercial revenue and a Phase 3 therapeutic program. Commercial cash flow from the Px business provides a cushion that reduces binary-Outcome risk typically associated with clinical-stage biotechs, while TLX591-Tx offers a high-upside therapeutic opportunity if the Phase 3 succeeds. What the recent data tells us Telix reported Group Q2 2026 revenue of $247 million, up 7% sequentially and 21% year-over-year; Precision Medicine revenue reached $202 million, up 30% YoY. Management reiterated FY 2026 guidance to exceed $1 billion in revenue. That puts current market capitalization — approximately $4.32 billion — at roughly a 4.3x multiple on implied forward revenue if guidance is met, a moderate multiple for a company combining recurring diagnostics and a Phase 3 oncology asset. On the clinical front, the company received FDA alignment to progress TLX591-Tx into Part 2 of the ProstACT Global Phase 3 trial and plans an IND amendment to initiate Part 2 enrollment in the U.S. (announcement 07/02/2026). The ProstACT SELECT Phase 1 results were published in Cancers (07/21/2026), showing a median radiographic progression-free survival of 8.8 months and a manageable safety profile — the kind of data that de-risks patient selection for the Phase 3 and supports the Part 2 design. There are additional corporate positives: near-completion of BiPASS enrollment and a strategic collaboration with Regeneron reported alongside a convertible bond refinancing that simplifies the capital structure (announced 07/20/2026). Board-level strengthening also occurred with the appointment of David Gill as Chair effective 08/31/2026, bringing experience in radiopharmaceuticals and capital markets. Technical and market context The stock trades near $11.98 (previous close $12.83) with a 52-week range of $6.28 - $13.11. Momentum indicators are neutral-to-positive: 10-day SMA $11.91, 50-day SMA $11.32, RSI ~52, and MACD showing bullish momentum. Average volumes have been rising; two-week average volume ~405k shares, which supports the idea of tradability around these levels. Short interest has fluctuated but days-to-cover remain low (roughly 1-2), so moves can be amplified in both directions. Valuation framing At a market cap of ~$4.32 billion and FY 2026 revenue guidance above $1 billion, Telix is trading at an enterprise multiple that is not extreme for a company with a growing, cash-generative diagnostics arm plus a Phase 3 therapeutic candidate. The reported PE of ~129 reflects limited trailing earnings (the business is investing heavily in pipeline and manufacturing). The more pragmatic forward view is to value Telix as a hybrid: a core diagnostics business that can justify a mid-single-digit revenue multiple and an optionality premium for TLX591-Tx and other pipeline assets. If TLX591-Tx advances cleanly through Part 2 and Pixclara achieves commercial traction in the U.S., the optionality could compress into tangible earnings growth, supporting the target price proposed below. Catalysts to watch (2-5) Trade plan Thesis: Buy into a hybrid commercial/pipeline company where Pixclara approval (commercial catalyst) and TLX591-Tx Phase 3 advancement (clinical catalyst) materially de-risk upside while existing Px revenue funds operations. Entry: $11.90. Stop: $10.00. Target: $17.00. Horizon: long term (180 trading days). I choose the long-term horizon because (a) commercial adoption and payer decisions for Pixclara will take several months to manifest in recurring revenue line items and (b) Part 2 enrollment, site activation and early safety signals for TLX591-Tx in the U.S. will require time. This timeline gives the business time to translate regulatory wins into measurable revenue and for clinical progress to be reflected in investor sentiment. Position sizing guidance: treat this as a high-risk, event-driven biotech trade — size appropriately (small-to-moderate position relative to total portfolio), and use the stop to control downside while allowing room for volatility around binary clinical and reimbursement events. Risks and counterarguments Counterargument: One could reasonably argue that the market has already priced these positives into the stock. Price is near a 52-week high, and institutional interest and momentum metrics are supportive. If Pixclara's approval and TLX591-Tx Part 2 advancement were fully expected by the market, the stock could trade sideways absent additional upside catalysts like early Phase 3 signals, rapid U.S. commercial uptake, or incremental partnerships. What would change my mind I would re-evaluate the Buy thesis under any of the following conditions: (1) meaningful delays or negative feedback from payers on Pixclara reimbursement that materially reduces 2026 revenue expectations; (2) early safety signals or design issues in Part 2 that force protocol changes or slow enrollment; (3) management guidance that lowers FY 2026 revenue materially below $1 billion; or (4) evidence that manufacturing capacity will not meet anticipated commercial demand. Conversely, quicker-than-expected reimbursement wins, robust Pixclara revenue prints, or positive interim Phase 3 signals would strengthen the bullish case and justify raising the target. Conclusion Telix offers a tradable long opportunity where a newly commercialized diagnostic (Pixclara) and an advancing Phase 3 therapeutic (TLX591-Tx) create a favorable risk-reward. The company already shows commercial momentum with Q2 2026 revenue of $247M (Precision Medicine $202M), and market cap of $4.32B implies a reasonable multiple if management converts regulatory wins into market share. My Buy recommendation is target-driven and time-boxed: enter at $11.90, stop at $10.00, target $17.00, and hold for the long term (180 trading days) to allow commercial uptake and Phase 3 enrollment to play out. Size positions cautiously; the upside is compelling, but pipeline and reimbursement execution will determine whether this becomes a multi-bagger or a volatile story.